Citicoline für Attention & Focus Difficulties

B Evidenz Mindestens eine randomisierte Studie unterstützt dies, mit überwiegend konsistenten Ergebnissen.

Researchers reviewing 14 studies found established evidence for improvements in attention, processing speed, and working memory with citicoline supplementation, particularly in elderly populations with existing cognitive complaints.

𝕏 LinkedIn

<\/script>\n

`; }, get iframeSnippet() { const domain = 'braincited.com'; const params = 'ingredient\u003Dciticoline\u0026condition\u003Dattention\u002Dfocus'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

Fazit

Key Study Findings

Randomized Controlled Trial Double-blind

Use of Citicoline in Attention-Deficit/Hyperactivity Disorder: A Pilot Study.

Dose: None vs.: placebo Outcome: ADHD symptom improvement Wirkung: None None

Population: pediatric patients aged 7-12 years diagnosed with ADHD

Other 12 weeks

Investigation of Cognitive Impairment in the Course of Post-COVID Syndrome.

Dose: 19.17% vs.: None Outcome: cognitive function Wirkung: None None

Population: Covid-19 during the pandemic period between 2020 and 2022

Systematic Review n=8137

Pharmacological Treatments for Cocaine Craving: What Is the Way Forward? A Systematic Review.

Dose: None vs.: None Outcome: Cocaine craving reduction Wirkung: None None

Population: Cocaine use disorder patients

Review

Cholinergic nervous system and glaucoma: From basic science to clinical applications.

Dose: None vs.: None Outcome: Mortality Wirkung: None None

Population: None

Review

[X-chromosome-linked ichthyosis associated to epilepsy, hyperactivity, autism and mental retardation, due to the Xp22.31 microdeletion].

Dose: None vs.: None Outcome: None Wirkung: None None

Population: None

Key Statistics

Studien

1600

Teilnehmer

↑

Positive

Bewertung

Referenced Papers

Use of Citicoline in Attention-Deficit/Hyperactivity Disorder: A Pilot Study. RCT

Clinical neuropharmacology None 2 Zitierungen

Investigation of Cognitive Impairment in the Course of Post-COVID Syndrome. Other

Diagnostics (Basel, Switzerland) 2023

Pharmacological Treatments for Cocaine Craving: What Is the Way Forward? A Systematic Review. Review

Brain sciences 2022 17 Zitierungen

Cholinergic nervous system and glaucoma: From basic science to clinical applications. Review

Progress in retinal … 2019 107 Zitierungen

[X-chromosome-linked ichthyosis associated to epilepsy, hyperactivity, autism and mental retardation, due to the Xp22.31 microdeletion]. Review

Revista de neurologia 2012 12 Zitierungen

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Übliche Dosierungen

general:: 250-500 mg/day
cognitivesupport:: 500-2,000 mg/day

Obergrenze: Well-tolerated up to 4,000 mg/day in clinical trials

In der Forschung untersuchte Dosierungen

Dosierung	Dauer	Wirkung	N
None	--	Neutral	--
19.17%	12 weeks	Positive	--
None	--	Mixed	8137
None	--	Positive	--
None	--	Mixed	--

Beste Einnahmezeit: Morning or split dose; can be taken with or without food

Safety & Side Effects

Gemeldete Nebenwirkungen

⚠ Headache
⚠ Insomnia (if taken late in the day)
⚠ Mild gastrointestinal discomfort
⚠ Rare: restlessness or overstimulation

Bekannte Wechselwirkungen

● Levodopa (may enhance dopaminergic effects)
● Cholinergic drugs (additive acetylcholine increase)
● Anticholinergics (may reduce citicoline effectiveness)

Tolerierbare Höchstaufnahmemenge: Well-tolerated up to 4,000 mg/day in clinical trials

Konsultieren Sie immer Ihren Arzt, bevor Sie ein Nahrungsergänzungsmittel einnehmen.Konsultieren Sie immer Ihren Arzt, bevor Sie ein Nahrungsergänzungsmittel einnehmen.

Frequently Asked Questions

Does Citicoline help with Attention & Focus Difficulties?

Based on 14 studies with 1,600 participants, there is moderate evidence from clinical studies that Citicoline may support Attention & Focus Difficulties management. Our evidence grade is B (Good Evidence).

How much Citicoline should I take for Attention & Focus Difficulties?

Studies have used various dosages. A commonly studied range is 250-500 mg/day. Always consult your healthcare provider before starting any supplement regimen.

Are there side effects of Citicoline?

Reported side effects may include Headache, Insomnia (if taken late in the day), Mild gastrointestinal discomfort, Rare: restlessness or overstimulation. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

How strong is the evidence for Citicoline and Attention & Focus Difficulties?

We rate the evidence as Grade B (Good Evidence). This rating is based on 14 peer-reviewed studies with 1,600 total participants. The overall direction of effect is positive.

Andere Inhaltsstoffe für Attention & Focus Difficulties

L-Theanine B Omega-3 Fatty Acids (DHA/EPA) C Bacopa monnieri C Phosphatidylserine C

Citicoline für andere Beschwerden

Memory Loss B

Kurzfazit

Evidence Strength72%

High confidence

Studienübersicht

RCT (1)Meta (0)Other (13)

Alternativen vergleichen

Sehen Sie, wie andere Inhaltsstoffe bei dieser Beschwerde abschneiden.

Alle Inhaltsstoffe ansehen für Attention & Focus Difficulties

Mehr erfahren

References

[1] Isabel Barros Hübner et al.. Clin Neuropharmacol. Use of Citicoline in Attention-Deficit/Hyperactivity Disorder: A Pilot Study. doi:10.1097/WNF.0000000000000602 PubMed
[2] Milena Dimitrova et al.. Diagnostics (Basel). 2023. Investigation of Cognitive Impairment in the Course of Post-COVID Syndrome. doi:10.3390/diagnostics13162703 PubMed
[3] Dângela Layne Silva Lassi et al.. Brain Sci. 2022. Pharmacological Treatments for Cocaine Craving: What Is the Way Forward? A Systematic Review. doi:10.3390/brainsci12111546 PubMed
[4] Muneeb A Faiq et al.. Prog Retin Eye Res. 2019. Cholinergic nervous system and glaucoma: From basic science to clinical applications. doi:10.1016/j.preteyeres.2019.06.003 PubMed
[5] M Carmen Carrascosa-Romero et al.. Rev Neurol. 2012. [X-chromosome-linked ichthyosis associated to epilepsy, hyperactivity, autism and mental retardation, due to the Xp22.31 microdeletion]. PubMed

FDA-Haftungsausschluss: Diese Aussagen wurden nicht von der Food and Drug Administration bewertet. Die Produkte und Informationen auf dieser Website sind nicht dazu bestimmt, Krankheiten zu diagnostizieren, zu behandeln, zu heilen oder zu verhindern. Die dargestellten Evidenzbewertungen basieren auf unserer Analyse veröffentlichter begutachteter Forschung und stellen keine medizinische Beratung dar. Konsultieren Sie immer Ihren Arzt, bevor Sie mit der Einnahme von Nahrungsergänzungsmitteln beginnen.